Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report

Table 1 Overview of the clinical symptoms, image findings, treatment, and prognosis in relevant research and the case in study

Ref.	Clinical symptoms	Image findings (computed tomography)	Treatment	Prognosis
Tanaka et al[9]	Anorexia, abdominal distension	Disseminated liver infiltrations	Palliative therapy	Died 10 d after diagnosis
Shan et al[10]	Anorexia, abdominal distension	Enlarged liver without individual lesion	Traditional medicine	Died 31 d after diagnosis
Yenıova et al[15]	Abdominal distension, weight loss	Multiple masses in the liver	Palliative care	Not stated
Bostanci et al[14]	Right upper quadrant abdominal pain, weight loss	Cystic lesion in the left lobe of the liver	Surgical excision	Discharged 4 d post- surgery without compliance to follow-up
Tanaka et al[11]	Fever, multiple sites of erythema with crusting on thetrunk region	Multiple poorlydefined irregularly shaped masses in the liver	Palliative therapy	Died 47 d after diagnosis
Case in study	No significant symptoms	Multiple heterogeneous masses and nodules in both lobes of the liver	Immunotherapy with combined nivolumab and ipilimumab	Died 9 mo after diagnosis